Better defining non-ischemic cardiomyopathy with functional mitral regurgitation to predict treatment outcomes
Official title: Improving Phenotypic Classification and Prediction of Treatment Outcomes in Patients with Non-ischemic Cardiomyopathy and Functional Mitral Regurgitation
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-11319841 · Data updated 2026-11-12
The team will use advanced heart MRI to better classify people with non-ischemic cardiomyopathy and functional mitral regurgitation so doctors can predict which treatments may work best.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 10, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $777,580 |
| NIH project number | 5R01HL170090-04 |
| Project ID | NIH-11319841 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with non-ischemic cardiomyopathy who have at least moderate functional mitral regurgitation and who can undergo cardiac MRI and clinical follow-up would be ideal candidates.
✕Less likely to help
Patients whose mitral regurgitation is primarily degenerative (primary valve disease), those with ischemic-only cardiomyopathy without a non-ischemic component, or people unable to have MRI may not benefit directly from this work.
What this research studies
You would get a detailed cardiac MRI to measure heart chamber size, pumping function, and tissue scarring more precisely than standard ultrasound. Researchers will combine those MRI results with clinical and outcome data to identify subtypes of non-ischemic cardiomyopathy and build models that predict how patients do after medical therapy or mitral valve procedures. The project focuses on linking imaging patterns to real outcomes like survival and symptom improvement to help guide treatment choices. The goal is clearer selection criteria for interventions such as percutaneous mitral repair (MitraClip) versus medical management.
Why it matters
Potential benefit: If successful, this could help doctors choose the right timing and type of mitral valve treatment and improve survival and symptoms for patients with heart failure and functional mitral regurgitation.
How similar studies have gone: Prior trials like MITRA-FR and COAPT produced mixed results for percutaneous mitral repair, and using cardiac MRI to refine patient selection is promising but not yet proven.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Kwon, Deborah — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Kwon, Deborah
Related research
Other NIH-funded projects on the same topics.
-
Improving treatment predictions for heart patients with mitral valve issues
This study is looking at how to better understand and treat heart problems in people with non-ischemic cardiomyopathy and leaky heart valves, using advanced imaging techniques to help doctors choose the best treatments for each patient.
-
Correcting cardiac microdomains to reverse non-ischemic heart failure
A gene therapy approach targeting calcium-handling microdomains in the heart is being tested to restore heart function in a large animal model of non-ischemic cardiomyopathy.
-
Improving heart function by correcting calcium handling in heart cells
This study is testing a new gene therapy that aims to fix how heart cells manage calcium in people with non-ischemic cardiomyopathy, using minipigs to see if improving a specific protein can help the heart work better and stay healthier.
-
Biological treatment to reduce ventricular arrhythmias in a pig model of heart disease
Aims to test if delivering heart-cell–derived exosomes into damaged heart tissue can reduce scar and prevent dangerous ventricular rhythms in a porcine model of chronic ischemic cardiomyopathy.
-
Repairing damaged heart tissue to stop dangerous ventricular rhythms after ischemic heart damage
The team is testing whether tiny particles from heart-derived cells can repair scarred heart tissue and stop life-threatening ventricular rhythms in people with ischemic cardiomyopathy.
-
Improving heart tissue to prevent dangerous heart rhythms
This study is looking at a new way to help people with chronic heart issues by using tiny particles from heart cells to improve the heart's electrical signals and reduce scar tissue, making it safer and more effective for patients with dangerous heart rhythms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.